Android Apple

Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer

By Yahoo! Finance   |   2 weeks ago
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer

The article discusses the impact of Lantern Pharma Inc. and other AI stocks. It also highlights the appointment of David Sacks as the "White House A.I. & Crypto Czar" under the new administration.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.